Ishibashi et al. confirmed that RCC overexpressed IL-6 and showed drug resistance under VEGFR-TKI treatment, and significant tumor regression was observed after blocking the IL-6 receptor (12). This evidence concerns the gene KDR and renal cell carcinoma.